Does a novel risk assessment model improve the stratification of cancer-associated thrombosis risk compared to the original Khorana Score in patients with cancer?
Patients with cancer in two unique US health care systems
Novel clinical risk assessment model (RAM) for cancer-associated thrombosis
Original Khorana Score (KS)
Cumulative incidence of venous thromboembolism (VTE) and pulmonary embolism/lower extremity deep vein thrombosis (PE/LE-DVT) at 6 monthshard clinical
A novel risk assessment model improves upon the original Khorana Score by better stratifying patients with cancer into high- and low-risk groups for venous thromboembolism at 6 months.
The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.Media: see text.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ang Li
Jennifer La
Sarah May
Journal of Clinical Oncology
Harvard University
Massachusetts Institute of Technology
University of Washington
Building similarity graph...
Analyzing shared references across papers
Loading...
Li et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d98849ed2e131d3c6841d2 — DOI: https://doi.org/10.1200/jco.22.01542